Linked Life Data

18208367

Source:http://linkedlifedata.com/resource/pubmed/id/18208367

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-1-22
pubmed:abstractText
Cannabinoids have been shown to exert beneficial actions in different animal models of multiple sclerosis (MS). However, the use of cannabinoids compounds in human therapy is greatly limited by their psychoactivity. Thus, new hopes in MS therapy have arisen from the evidence for a cannabinoid receptor, termed CB2, which is devoid of psychoactive effects in animal models.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1744-7631
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
185-95
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Therapeutic potential of CB2 targeting in multiple sclerosis.
pubmed:affiliation
Grupo de Neuroinmunología, Instituto Ramón y Cajal, CSIC-Avda Dr Arce, 37, 28002 Madrid, Spain. docagne@cajal.csic.es
pubmed:publicationType
Journal Article, Review